Mustang Bio (MBIO) Other financing activities (2018 - 2025)

Mustang Bio (MBIO) posted quarterly Other financing activities of $45000.0 for Q3 2024, up 2150.0% quarter-over-quarter from $2000.0 in Q2 2024.

Mustang Bio (MBIO) Other financing activities (2018 - 2025) Analysis & Trends

Mustang Bio (MBIO) has reported Other financing activities for 5 consecutive years, with $45000.0 the latest figure, recorded in Q3 2024.

In Q3 2024, Other financing activities changed N/A year-over-year to $45000.0; the TTM figure through Jun 2025 stood at $45000.0 (up 1400.0% YoY), while the FY2024 annual figure was $48000.0, changed N/A from the prior year.
Other financing activities advanced to $45000.0 in Q3 2024 per MBIO's latest filing, from $2000.0 in the prior quarter.
Across five years, Other financing activities topped out at $180000.0 in Q3 2020 and bottomed at $1000.0 in Q1 2024.
Historically, Other financing activities has averaged $101333.3 across 4 years, with a median of $116000.0 in 2022.
Annual changes were most pronounced in 2021 — Other financing activities declined 6.51% — and 2022, when it plunged 40.4%.
Mustang Bio's Other financing activities stood at $180000.0 in 2020, then decreased by 16.11% to $151000.0 in 2021, then sank by 40.4% to $90000.0 in 2022, then slumped by 50.0% to $45000.0 in 2024.
Business Quant data shows MBIO's Other financing activities at $45000.0 in Q3 2024, $2000.0 in Q2 2024, and $1000.0 in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Mustang Bio	3.90 Mn	3.90 Mn	-

Download Data